Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 4/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649859 | 0.89 | CHRM4 (0.43) | CYP11B1CYP11B2STAT3GPR119CHRM4 | |
| SCHEMBL29435672 | 0.89 | CHRM4 (0.43) | CYP11B1CYP11B2STAT3GPR119CHRM4 | |
| SCHEMBL30900483 | 0.80 | NOTUM (0.61) | POLBKDM1A | |
| SCHEMBL552069 | 0.80 | NOTUM (0.61) | POLBKDM1A | |
| SCHEMBL25633529 | 0.79 | CYP11B2 (0.61) | CYP11B1CYP11B2 | |
| SCHEMBL31092774 | 0.79 | STAT3 (0.43) | CYP11B1CYP11B2STAT3CHRM4POLB | |
| SCHEMBL15811843 | 0.79 | BIRC2 (0.41) | GPR119DRD2 | |
| SCHEMBL15811841 | 0.79 | BIRC2 (0.41) | GPR119DRD2 | |
| SCHEMBL21056682 | 0.79 | CYP11B2 (0.55) | CYP11B1CYP11B2HTR2C | |
| SCHEMBL5960591 | 0.78 | CHRM4 (0.47) | CYP11B1CYP11B2GPR119CHRM4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | CERVELLO THERAPEUTICS, LLC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2023-05-11 | — | — | US | disclosed |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114072395-A | Heterocyclic compounds and their use for treating helminth infections and diseases | 新基公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| WO-2020219871-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
| EP-2205610-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009147476-A1 | NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | MATRIX LABORATORIES LTD. (IN) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147476-A1 | NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | MATRIX LABORATORIES LTD. (IN) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP11B1 20/4885CYP11B2 19/4885STAT3 2804/4885 |
| US-20200339559-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | CYP11B1 46/4885CYP11B2 44/4885STAT3 3796/4885 |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | CYP11B1 46/4885CYP11B2 44/4885STAT3 3796/4885 |
| US-11505548-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | CYP11B1 46/4885CYP11B2 44/4885STAT3 3796/4885 |
| US-11912719-B2 | Substituted isoquinolines as rock kinase inhibitors | ROCK1, ROCK2, CIT | CYP11B1 487/4885CYP11B2 404/4885STAT3 3328/4885 |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CYP11B1 996/4885CYP11B2 1641/4885STAT3 539/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP11B1 20/4885CYP11B2 19/4885STAT3 2804/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | CYP11B1 46/4885CYP11B2 44/4885STAT3 3796/4885 |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | CYP11B1 46/4885CYP11B2 44/4885STAT3 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.